Law360, New York (August 10, 2011, 3:21 PM ET) -- A New York federal judge refused Wednesday to dismiss a putative securities class action stemming from a $2.3 billion civil and criminal fine Pfizer Inc. paid for illegally marketing off-label uses of four drugs and offering doctors kickbacks to promote the medications.
The company had argued that the “plaintiffs’ prolix and confusing complaint — their third — [failed] to remedy the shortcomings identified” in an April order instructing them to refer only to certain exhibits necessary for the understanding of the allegations.
Pfizer pointed out that...
Pfizer Can't Shake Investor Suit Over Off-Label Marketing
To view the full article, take a free trial now.
